Based on our findings and the existing literature, we suggest that suppression of the identified AML drug resistant-specific markers (i.e., RARA and RELA) and activation of the sensitivity-specific marker (i.e., PIK3CD) may offer essential guidance for improving chemotherapy. The gene discussed is RARA; the disease is acute myeloid leukemia.